Nanotherapeutics for drug targeting
AssigneePresident and Fellows of Harvard College
InventorsDonald E. Ingber, Netanel Korin, Mathumai Kanapathipilai, Oktay Uzun, Anne-Laure Papa
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for targeted controlled drug release. The compositions and methods can be used for treating or imaging vascular stenosis, stenotic lesions, occluded lumens, embolic phenomena, thrombotic disorders and internal hemorrhage.
Claims25
An aggregate comprising a plurality of nanoparticles, wherein the aggregate disaggregates under a predetermined stimulus selected from the group consisting of ultrasound, mechanical strain, vibration, magnetic field, radiation, temperature, ionic strength, pH, pressure, turbulence, change in flow, flow rate, or chemical or enzymatic activation.
2-81. (canceled)
The aggregate of claim 2, wherein the molecule is absorbed/adsorbed on the surface of the aggregate or the nanoparticle constituent of the aggregate.
The aggregate of claim 2, wherein the molecule is encapsulated in the aggregate or the nanoparticle constituent of the aggregate.
The aggregate of claim 2, wherein the molecule is covalently linked to the aggregate or the nanoparticle constituent of the aggregate.
The aggregate of claim 2, wherein the aggregate or the nanoparticle constituent of the aggregate comprises a surface reactive group for linking with the molecule.
The aggregate of claim 2, wherein the molecule is biologically active.
The aggregate of claim 2, wherein the molecule is a therapeutic agent, or an analog, derivative, prodrug, or a pharmaceutically acceptable salt thereof.
The aggregate of claim 2, wherein the molecule is a targeting ligand.
The aggregate of claim 2, wherein the aggregate comprises both a therapeutic agent and an imaging or contrast agent.
The aggregate of claim 2, wherein the molecule is a prodrug and the aggregate further comprises a reagent for activating the prodrug.
Dependencies are inferred from the claim text.